Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120958 | 0.83 | MTNR1A (0.42) | APPMERTKCES2CES1 | |
| SCHEMBL8034298 | 0.77 | CRHR1 (0.41) | APPL3MBTL1CES2CES1 | |
| SCHEMBL12888669 | 0.71 | L3MBTL1 (0.48) | L3MBTL1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1120950 | 0.70 | CES2 (0.41) | APPL3MBTL1CES2CES1 | |
| SCHEMBL20989804 | 0.70 | APP (0.52) | APPCES2CES1 | |
| SCHEMBL1120954 | 0.68 | L3MBTL1 (0.76) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL1121053 | 0.67 | VSIR (0.47) | L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL29446279 | 0.67 | SMN1; SMN2 (0.38) | L3MBTL1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL25334623 | 0.66 | KDM4E (0.46) | L3MBTL1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL17622145 | 0.66 | LMNA (0.48) | L3MBTL1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162988-B2 | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES, INC. (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-1840121-B1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2039687-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | TORAY INDUSTRIES (JP) | 2012-05-02 | — | — | EP | disclosed |
| CN-101472580-B | Therapeutic or prophylactic agent for allergic dermatitis | TORAY INDUSTRIES | 2011-08-24 | — | — | CN | disclosed |
| CN-101472900-B | Therapeutic or prophylactic agent for multiple sclerosis | TORAY INDUSTRIES | 2011-07-27 | — | — | CN | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-2042171-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | Toray Industries, Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2039687-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | Toray Industries, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2033637-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | Toray Industries, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| CN-101128436-A | Glycine derivative and use thereof | TORAY INDUSTRIES (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1840121-A1 | GLYCINE DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | APP 912/4885L3MBTL1 2740/4885MERTK 2227/4885 |
| US-20130150390-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | APP 912/4885L3MBTL1 2740/4885MERTK 2227/4885 |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | GNMT, SI, SLC7A11 | APP 731/4885L3MBTL1 1737/4885MERTK 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.